WO1998038986A3 - Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections - Google Patents

Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections Download PDF

Info

Publication number
WO1998038986A3
WO1998038986A3 PCT/EP1998/001241 EP9801241W WO9838986A3 WO 1998038986 A3 WO1998038986 A3 WO 1998038986A3 EP 9801241 W EP9801241 W EP 9801241W WO 9838986 A3 WO9838986 A3 WO 9838986A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
medicament
viral infections
derivatives
prevention
Prior art date
Application number
PCT/EP1998/001241
Other languages
French (fr)
Other versions
WO1998038986A2 (en
Inventor
Akira Matsumori
Original Assignee
Boehringer Mannheim Gmbh
Akira Matsumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh, Akira Matsumori filed Critical Boehringer Mannheim Gmbh
Priority to AU73324/98A priority Critical patent/AU7332498A/en
Publication of WO1998038986A2 publication Critical patent/WO1998038986A2/en
Publication of WO1998038986A3 publication Critical patent/WO1998038986A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Medicament for preventive and therapeutic treatment of viral infections which comprises as an active ingredient a substance selected from the group consisting of carvedilol, optically active isomers thereof, its hydroxy carbazole derivatives and pharmaceutically acceptable salts thereof.
PCT/EP1998/001241 1997-03-06 1998-03-05 Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections WO1998038986A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73324/98A AU7332498A (en) 1997-03-06 1998-03-05 Medicament for preventive and therapeutic treatment of viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP97/51474 1997-03-06
JP05147497A JP4126345B2 (en) 1997-03-06 1997-03-06 Preventive and therapeutic agents for viral infections

Publications (2)

Publication Number Publication Date
WO1998038986A2 WO1998038986A2 (en) 1998-09-11
WO1998038986A3 true WO1998038986A3 (en) 1999-01-14

Family

ID=12887959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001241 WO1998038986A2 (en) 1997-03-06 1998-03-05 Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections

Country Status (3)

Country Link
JP (1) JP4126345B2 (en)
AU (1) AU7332498A (en)
WO (1) WO1998038986A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058877A1 (en) * 2000-02-14 2001-08-16 Mochida Pharmaceutical Co., Ltd. Interferon ω production potentiators
JP2008514611A (en) 2004-09-23 2008-05-08 ワイス Derivatives of carbazole and cyclopentaindole for treating infection with hepatitis C virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012177A1 (en) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Antioxydant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012177A1 (en) * 1992-12-01 1994-06-09 Smithkline Beecham Corporation Antioxydant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "Viral myocarditis: Balance between viral infection and immune response", CAN. J. CARDIOL., vol. 12, no. 10, October 1996 (1996-10-01), CANADA, pages 935 - 943, XP002072741 *

Also Published As

Publication number Publication date
JP4126345B2 (en) 2008-07-30
AU7332498A (en) 1998-09-22
WO1998038986A2 (en) 1998-09-11
JPH10251148A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
ES2088312T3 (en) CONTROLLED RELEASE FORMULATION CONTAINING TRAMADOL.
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
NZ514574A (en) Novel method of treatment
AU1227899A (en) Osmotic medicament releasing system
MX9706449A (en) Pharmaceutical composition for piperidinoalkanol compounds.
AU3990797A (en) Sustained release formulation
EP0392959A3 (en) Use of sertindole for the treatment of schizophrenia
NO971206D0 (en) Prolonged-frigjöringsformulering
WO2003015779A3 (en) Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
WO2001098279A3 (en) Bis-arylsulfones
CA2253130A1 (en) A medicament for treating obesity and improving lipid metabolism
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
WO1999004772A3 (en) Use of levobupivacaine
EP1440691A3 (en) Treatment of neurotic disorders
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
AR023687A1 (en) A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
GR3025568T3 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia.
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
AU7493896A (en) A pharmaceutical composition for the treatment of autoimmune diseases
CA2272732A1 (en) Hemorrhoidal treatment composition
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538162

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA